Primary study · included by 1 review
A phase 2, single-arm trial evaluating 131 I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer.
Liu 2024 · Liu Richard F, Ferrario Cristiano, Fallah Parvaneh, et al. · Nuclear medicine communications · 2024
Included by
The review does not say which of its outcomes this study informs.
1 including review in total.